Combined Active Treatment in Type 2 Diabetes With NASH

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

Also called NCT04639414

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 192 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04639414
  • EudraCT 2019-001987-31
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04639414. Randomized; triple masking; primary purpose treatment. Start 2021-03-26 (actual); primary completion 2025-01-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combined Active Treatment in Type 2 Diabetes With NASH
Acronym
COMBAT_T2_NASH
Condition
Non-alcoholic Steatohepatitis (NASH)
Condition
Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention (Drug)
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
Intervention (Drug)
Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
Intervention (Drug)
Placebo matching empagliflozin and placebo pen injector matching semaglutide
Lead sponsor
German Diabetes Center (class: other)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
German Center for Diabetes Research (class: other)
Collaborator
Federal Ministry of Health, Germany (class: other government)
Collaborator
Ministry of Innovation, Science and Research in North Rhine-Westphalia (class: not stated)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04639414
Content hash
5832a8ed5424d42066e5dfe0ebbdb6c23b1823ebb2838b3a125eef1673a9526b